Novartis OTC Stock Executives


USD 84.85  0.84  1.00%   

Novartis employes about 110 K people. The company is managed by 50 executives with total tenure of roughly 422 years, averaging almost 8.0 years of service per executive having 2200.0 employees per reported executive. Evaluation of Novartis management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Novartis Ag Basl future performance.
Additionally, see Stocks Correlation.
  Chris Ilsley  CEO
President CEO
  Elizabeth Barrett  CEO
CEO, Novartis Oncology
  Francesco Balestrieri  CEO
CEO of Sandoz, Member of the Executive Committee

Novartis Management Team Effectiveness

Novartis Ag Basl has return on total asset (ROA) of 6.51 % which means that it generated profit of $6.51 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 43.06 %, meaning that it generated $43.06 on every $100 dollars invested by stockholders. Novartis management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Novartis Workforce Comparison

Novartis Ag Basl is considered to be number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is now estimated at about 298,595. Novartis totals roughly 110,000 in number of employees claiming about 37% of equities under Drug Manufacturers—General industry.

Novartis Profit Margins

The company has Profit Margin (PM) of 45.63 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 24.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.24.

Novartis Ag Basl Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Novartis Ag Basl Price Series Multiplication is a cross multiplication of Novartis price series and its benchmark/peer.

Novartis Notable Stakeholders

A Novartis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novartis often face trade-offs trying to please all of them. Novartis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novartis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Chris Ilsley - President CEOProfile
Elizabeth Barrett - CEO, Novartis OncologyProfile
Francesco Balestrieri - CEO of Sandoz, Member of the Executive CommitteeProfile
Paul Hudson - CEO of Novartis Pharmaceuticals, Member of the Executive CommitteeProfile
Susanne Schaffert - CEO Novartis Oncology, Member of the Executive CommitteeProfile
Bruno Strigini - CEO of Novartis Oncology, Member of the Executive CommitteeProfile
Michael Ball - CEO of Alcon, Member of the Executive CommitteeProfile
Joseph Jimenez - CEO, Member of the Executive CommitteeProfile
Daniel Vasella - Honorary Chairman of the BoardProfile
Joerg Reinhardt - Chairman of the BoardProfile
Alex Krauer - Honorary Chairman of the BoardProfile
Ulrich Lehner - Vice Chairman of the Board of Directors, Non-Executive DirectorProfile
Mark Fishman - Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)Profile
Andre Wyss - Member of the Executive Committee, Novartis Business Services and Country President for SwitzerlandProfile
James Bradner - President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive CommitteeProfile
Harry Kirsch - CFOProfile
Ton Buechner - Non-Executive Independent DirectorProfile
Pierre Landolt - Member of the Board of DirectorsProfile
Elizabeth Doherty - Non-Executive Independent DirectorProfile
Srikant Datar - Member of the Board of DirectorsProfile
Dimitri Azar - Member of the Board of DirectorsProfile
Frans Houten - Non-Executive Independent DirectorProfile
Nancy Andrews - Non-Executive Independent DirectorProfile
Enrico Vanni - Member of the Board of DirectorsProfile
Andreas Planta - Member of the Board of DirectorsProfile
Ann Fudge - Member of the Board of DirectorsProfile
Verena Briner - Non-Executive Independent Member of the BoardProfile
Steven Baert - Head of HRProfile
Richard Francis - Member of the Executive Committee and Division Head, SandozProfile
Erwin Vanhaecke - Head Novartis Group QualityProfile
Charlotte PamerWieser - Corporate SecretaryProfile
Shannon Klinger - Chief Risk and Compliance Officer, Group General CounselProfile
Samir Shah - Global Head Investor RelationsProfile
David Epstein - Member of the Executive Committee, Division Head, PharmaceuticalsProfile
Steffen Lang - Global Head of Novartis Technical Operations, Member of the Executive CommitteeProfile
Brian McNamara - Member of the Management Board, Division Head, Novartis OTCProfile
Michele Galen - Head CommunicationsProfile
Charles Sawyers - Non-Executive Independent Member of the BoardProfile
John Tsai - Head of Global Drug Development and Chief Medical Office, Member of the Executive CommitteeProfile
Bertrand Bodson - Chief Digital Officer, Member of the Executive CommitteeProfile
Robert Weltevreden - Head of Novartis Business Services (NBS), Member of the Executive CommitteeProfile
Vasant Narasimhan - Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive CommitteeProfile
Jeffrey George - Member of the Executive Committee and Division Head, SandozProfile
Peter Kornicker - Chief Compliance OfficerProfile
William Winters - Non-Executive Independent Member of the BoardProfile
George Gunn - Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate ResponsibilityProfile
Paul Arkel - Head of Corporate Strategy and External AffairsProfile
Klaus Moosmayer - Chief Ethics Risk and Compliance Officer, Member of the Executive CommitteeProfile
Felix Ehrat - General Counsel and General Counsel of Novartis International AgProfile
Andrin Oswald - Member of the Executive Committee, Division Head, Vaccines and DiagnosticsProfile

About Novartis Management Performance

The success or failure of an entity such as Novartis Ag Basl often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics protein- or other biotechnology-based products, including biosimilars and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
The data published in Novartis' official financial statements usually reflect Novartis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novartis Ag Basl. For example, before you start analyzing numbers published by Novartis accountants, it's critical to develop an understanding of what Novartis' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Novartis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novartis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis Ag Basl. Please utilize our Beneish M Score to check the likelihood of Novartis' management to manipulate its earnings.

Novartis Workforce Analysis

Traditionally, organizations such as Novartis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novartis within its industry.

Novartis Manpower Efficiency

Return on Novartis Manpower

Revenue Per Employee481.8 K
Revenue Per Executive1.1 B
Net Income Per Employee219.8 K
Net Income Per Executive483.6 M
Working Capital Per Employee11.6 K
Working Capital Per Executive25.6 M
Additionally, see Stocks Correlation. Note that the Novartis Ag Basl information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Novartis OTC Stock analysis

When running Novartis Ag Basl price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
187.7 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Novartis Ag Basl is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine Novartis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.